Acquired Autoimmune Hemolytic Anemia Market Outlook 2025–2034: Identifying Growth Drivers, Technology Trends, and Policy Impact
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Acquired Autoimmune Hemolytic Anemia Market Growth Performance Trended Historically, And What Lies Ahead?
The market size for acquired autoimmune hemolytic anemia has experienced robust growth recently. The market is projected to expand from $2.01 billion in 2024 to $2.14 billion in 2025, with a compound annual growth rate (CAGR) of 6.5%. The growth observed in the historic period is due to a surge in the diagnosis rates, increased reports of secondary AIHA, wider expansion of hospital hematology units, government and regulatory backing, and heightened investment in hematology.
We anticipate robust expansion in the market size for acquired autoimmune hemolytic anemia in the coming years. The market is expected to flourish to $2.81 billion by 2029, representing a compound annual growth rate (CAGR) of 7.1%. This predicted growth during the forecast period is due to factors such as rising autoimmune disease rates, increasing comprehension of the complement system’s function, more partnerships formed between biopharma and academia, a rise in personalized medicine usage, and an expanding older population. The anticipated trends for this forecast period encompass the embracing of specialized biologic therapies, progress in complement pathway inhibitors, and the integration of AI and data analysis in disease management. Further trends involve the utilization of AI for designing clinical trials and innovation in orphan drugs.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24132&type=smp
What Are the Core Market Drivers Propelling Growth in the Acquired Autoimmune Hemolytic Anemia Industry?
The surge in autoimmune disorders is anticipated to fuel the expansion of the acquired autoimmune hemolytic anemia market. Autoimmune disorders occur when the body’s immune system mistakenly attacks its own healthy cells and tissues, viewing them as harmful intruders. The rapid growth of these disorders is primarily due to escalating environmental factors and changes in lifestyle, which can interfere with the regulation of the immune system. As autoimmune diseases escalate, the incidence of acquired autoimmune hemolytic anemia also increases, with individuals suffering from autoimmune disorders having a higher likelihood of developing secondary AIHA due to immune system disruption. For example, the autoimmune registry, a US-based entity that focuses on collecting and assessing data relating to autoimmune conditions, reported in 2022 that the number of patients identified with multiple autoimmune conditions increased from 52% in 2021 to 55% in 2022. Consequently, the growth of the acquired autoimmune hemolytic anemia market is influenced by the increasing occurrence of autoimmune disorders.
How Is the Acquired Autoimmune Hemolytic Anemia Market Segmented?
The acquired autoimmune hemolytic anemia market covered in this report is segmented –
1) By Diagnosis Method: Complete Blood Count, Peripheral Blood Smear, Direct Coombs Test, Indirect Coombs Test
2) By Treatment Type: Corticosteroids, Immunosuppressive Agents, Intravenous Immunoglobulin, Rituximab
3) By Severity: Mild, Moderate, Severe
4) By End User: Hospitals, Specialty Clinics, Research Institutions
Subsegments:
1) By Complete Blood Count: Hemoglobin Level, Hematocrit (HCT), Reticulocyte Count, White Blood Cell Count, Platelet Count
2) By Peripheral Blood Smear: Spherocytes, Polychromasia, Schistocytes, Increased Reticulocyte Count
3) By Direct Coombs Test: Immunoglobulin G Coombs Test, Immunoglobulin M Coombs Test, Complement Coombs Test
4) By Indirect Coombs Test: Screening For Alloantibodies, Detection Of Sensitizing Antibodies, Crossmatch Testing
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=24132&type=smp
Which Regions Are Driving the Next Phase of the Acquired Autoimmune Hemolytic Anemia Market Growth?
North America was the largest region in the acquired autoimmune hemolytic anemia market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired autoimmune hemolytic anemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Market Trends and Innovations Are Shaping the Future of the Acquired Autoimmune Hemolytic Anemia Industry?
Key players in the acquired autoimmune hemolytic anemia market are concentrating their efforts on advancing targeted treatments, like humanized monoclonal antibodies, in order to increase the effectiveness of their treatment, minimize adverse reactions, and offer more individualized solutions for those suffering from autoimmune hemolytic anemia. These humanized monoclonal antibodies are synthetic proteins created in a lab that imitate human antibodies. They mainly consist of human structures with minor parts of non-human (typically mouse) antibodies incorporated to boost their ability to specifically target antigens and to limit rejection by the immune system. Sanofi, a French healthcare firm, in February 2022, was granted approval by the U.S. Food and Drug Administration (FDA), a US government agency, for their product Enjaymo (sutimlimab-jome). This marks the first and only treatment for cold agglutinin disease (CAD), which is a rare form of autoimmune hemolytic anemia. Enjaymo action mechanism involves selective inhibition of C1s in the classical complement pathway, preventing the immune system from attacking and eliminating healthy red blood cells. This in turn reduces the necessity for blood transfusions in patients with CAD. Notably, Enjaymo specifically inhibits C1-activated hemolysis without interfering with the lectin or alternative complement pathways.
View the full report here:
How Is the Acquired Autoimmune Hemolytic Anemia Market Defined and What Are Its Core Parameters?
Acquired autoimmune hemolytic anemia (AIHA) is a rare disorder that causes anemia when the body’s immune system unintentionally targets and kills its own red blood cells it is frequently brought on by infections, autoimmune disorders, malignancies, or specific drugs, and it can appear suddenly or gradually. This happens as a result of the body producing antibodies that attack its own red blood cells, causing hemolysis, or the premature breakdown of those cells.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24132
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
